WorksheetsLesson 25
Total questions: 8
Worksheet time: 80secs
1. What type of clinical trial was used?
Phase 1b, randomized, double-blind
Phase 2, non-randomized, uncontrolled, single-blind
Phase 1b, randomized, placebo-controlled, single-blind
Phase 2, randomized, placebo-controlled, double-blind
2. What was the primary endpoint?
Appetite and cachexia symptoms
Change from baseline in body weight
Digital measures of physical activity
Safety
3. Which group had a median difference of 2.81 kg of weight gain as compared to the placebo group?
Ponsegromab 100 mg
Ponsegromab 200 mg
Ponsegromab 400 mg
All the ponsegromab groups
4. How many patients experienced adverse effects of any cause?
80% in the ponsegromab groups and 70% in the placebo group
22 to 40% in the ponsegromab groups and 24% in the placebo group
4 to 11% in the ponsegromab groups and 9% in the placebo group
67 to 74% in the ponsegromab groups and 80% in the placebo group
5. What type of clinical trial was used?
Phase 2b randomized, double-blind, placebo-controlled trial
Phase 2a randomized, double-blind, uncontrolled trial
Phase 2a randomized, double-blind, placebo-controlled trial
Phase 2a randomized, single-blind, placebo-controlled trial
6. What was the primary endpoint?
Relative liver fat change
Change in body weight change at 24 weeks
Change in insulin sensitivity and lipid metabolism
Change in visceral adipose tissue
7. The relative percentage of hepatic fat fraction in the 8 mg RETA at 48 weeks was?
-57.0%
-81.4%
-81.7%
-86.0%
8. Which answer is INCORRECT?
The safety profile of retatrutide in people with MASLD was similar to that observed previous trials of people with obesity
There were no hepatotoxicity signals in the overall obesity trial population or in the subset of participants with MASLD through 48 weeks
Several cases of patients with advanced fibrosis or cirrhosis in the group with the higher doses of RETA were reported
Mild-to-moderate gastrointestinal events were the most frequently reported adverse events
